The full total results support the advantages of paclitaxel-eluting stents in diabetic patients.

TAXUS, TAXUS Express2, Express, Liberte, PROMUS and Component are trademarks of Boston Scientific Company or its affiliates. XIENCE is usually a trademark of Abbott Laboratories Group of Companies. The TAXUS Liberte Stent has received an indication for use in diabetic patients in CE-Marked countries. In the United States, the TAXUS Express, TAXUS Liberte and PROMUS Stents aren’t specifically indicated for use in diabetic patients.. Clinical trial comparing Boston Scientific’s coronary stent systems Boston Scientific Company today welcomed one-12 months data from the SPIRIT IV clinical trial comparing the XIENCE V) )) Everolimus-Eluting Coronary Stent System to the TAXUS) Express2 Paclitaxel-Eluting Coronary Stent System.Kvale, MD, FCCP, President of the American University of Chest Physicians. today outlined its essential strategic priorities for 2012, with a solid focus on traveling the global commercial worth of its diabetes franchise. In a display at the 30th Annual J.P. Morgan Healthcare Conference in SAN FRANCISCO BAY AREA, Amylin President and CEO Daniel M. Bradbury highlighted measures the company is taking to get ready for the planned United States and includes a Prescription Drug User Fee Action date of January 28, 2012. In addition, Mr. ‘We have a truly extraordinary chance at Amylin, as we embark on a year where we are ready to deliver the 1st ever once-weekly therapy in the U.S. Bradbury. ‘With the addition of BYDUREON in the U.S., we will solidify our position simply because a driving force in the fight against this rising global epidemic.